Tuesday Mar 07, 2023
FTC Cornering PBMs to Improve Pharmacy Care | PBM Reform
Special Guest:
Lindsay Bealor Greenleaf, J.D., M.B.A.,
Vice President and Head of Policy with ADVI Health Inc.
Why now: This week U.S. Sens. Chuck Grassley (R-IA) and Maria Cantwell (D-WA) introduced two bills that seek to hold pharmacy benefit managers (PBMs) accountable for opaque practices that contribute to high drug prices for consumers.
Lindsay Bealor Greenleaf, J.D., M.B.A.,
Vice President and Head of Policy with ADVI Health Inc.
Why now: This week U.S. Sens. Chuck Grassley (R-IA) and Maria Cantwell (D-WA) introduced two bills that seek to hold pharmacy benefit managers (PBMs) accountable for opaque practices that contribute to high drug prices for consumers.
Expert commentary: Lindsay Bealor Greenleaf, J.D., M.B.A., vice president and head of policy with ADVI can dive deep into a discussion on PBMs expanding on the following points:
1) PBMs were completely spared in the IRA while the people who actually make drugs got hit with unprecedented government price setting
2) Fortunately, PBMs will now face scrutiny on the Hill, including Prescription Pricing for the People Act (S. 113) and the PBM Transparency Act (S. 127) with new bills and “noisy” hearings
3) PBMs are also in hot seat with the FTC (from Lindsay’s perspective, the FTC is “incredibly hostile towards PBMs right now”)
Are these topics areas you’d like to explore? If yes, I’d like to line up a time for you to connect with Lindsay in the coming weeks. I look forward to your feedback on your interest in a podcast episode with our ADVI experts.
Reference: